

Amendments to the Specification:

Please replace the paragraph beginning at page 28, line 20, with the following:

--All peptides used in the following examples were produced by Research Genetic, Inc. (Huntsville, Alabama) using solid state methodology and purified on HPLC columns to > 90% purity using conventional methods. PLP1 peptide (HSLGKWLGH~~PNKF~~: ~~SEQ. ID No. 1~~ SEQ ID NO:1) encompasses an encephalitogenic sequence corresponding to aa residues 139-151 of naturally occurring proteolipid protein. PLP-LR (~~HSLGKLLGRPNKF:SEQ. ID No. 2~~) (HSLGKLLGRPNKF: SEQ ID NO:2) is an analog of PLP1 in which Trp144 and His147 were replaced with Leu and Arg (underlined), respectively. PLP1 and PLP-LR bind well to I-A^S class II molecules (i. e. an MHC class II structure produced by a specific strain of mice). PLP2 peptide (~~NTW TTCQSI AFPSK:SEQ. ID No. 3~~) (NTW TTCQSI AFPSK: SEQ ID NO:3) encompasses an encephalitogenic sequence corresponding to aa residues 178-191 of PLP. This peptide also binds to I-A^S class II molecules and induces EAE in SJL mice. HA peptide (sequence not shown) corresponds to aa residues 110-120 of the hemagglutinin of the Influenza virus. HA binds to I-E^D class II molecules and is used here as control peptide.--

Please cancel the present "SEQUENCE LISTING", "Page 1", submitted May 30, 2008, and insert therefor the accompanying paper copy of the Substitute Sequence Listing, page numbers 1 to 2, at the end of the application.